Loading data for IGC — first visit, this takes a few seconds.

알림

IGC Pharma Inc. (IGC)

NYSE American: IGC · 실시간 가격 · USD

0.29

+0.01 (3.57%)

종가 기준: Aug 12, 2026, 8:00 PM

3.57% (1D)

데이터 없음

매수호가	0.28
시가총액	29.84M
매출 (ttm)	1.11M
순이익 (ttm)	-6.45M
베타	0.46
EPS (ttm)	-0.06
P/E (ttm)	n/a
선행 P/E	-3.36
P/B (ttm)	4.61
P/S (ttm)	26.98
Earnings Date	n/a

매도호가	0.28
거래량	1,623,338
평균 거래량 (20일)	587,303
시가	0.28
전일 종가	0.28
일중 범위	0.28 - 0.29
52주 범위	0.24 - 0.50
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

IGC 소개

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheim...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 May 24, 2006

직원 수 70

상장 거래소 NYSE American

티커 IGC

웹사이트 https://igcpharma.com

전체 기업 정보

재무 실적

2025년 IGC Pharma의 매출은 1.27M로, 전년 1.34M 대비 -5.5% 감소했습니다. 순이익은 -7.12M로, -45.22% 감소했습니다.

재무제표

어닝 서프라이즈

IGC Pharma가 May 15, 2026에 분기 실적을 발표했습니다:

매출 $317K 예상치 하회 $0, 및 -3.94% 전년 대비 감소.

EPS -0.02 예상치 하회 0.00, 및 0.00% 전년 대비 성장.

뉴스

4개월 전 · TipRanks

IGC Pharma, New to The Street launch 12-part national media partnership

New to The Street announced a strategic 12-part media partnership with IGC Pharma (IGC). The multi-faceted campaign is designed to elevate IGC Pharma’s visibility across institutional and retail inves...

5개월 전 · Zacks

electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates

electroCore (ECOR) delivered earnings and revenue surprises of +1.45% and -0.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

5개월 전 · Zacks

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for ...

5개월 전 · Zacks

Merck KGaA (MKKGY) Lags Q4 Earnings Estimates

Merck KGaA (MKKGY) delivered earnings and revenue surprises of -40.43% and +0.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

5개월 전 · TipRanks

IGC Pharma expands Phase 2 CALMA trial with new clinical site

IGC Pharma (IGC) announced the addition of Visionary Investigators Network as a clinical research site participating in the Company’s Phase 2 CALMA trial evaluating IGC-AD1 for the treatment of agitat...

2 페이지 중 1

IGC Pharma Inc. (IGC)